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A B S T R A C T
Glutamate and GABA play an important role in substance dependence. However, it remains unclear whether this
holds true for diﬀerent substance use disorders and how this is related to risk-related traits such as impulsivity.
We, therefore, compared Glx (as a proxy measure for glutamate) and GABA concentrations in the dorsal anterior
cingulate cortex (dACC) of 48 male cigarette smokers, 61 male smoking polysubstance users, and 90 male
healthy controls, and investigated the relationship with self-reported impulsivity and substance use. Glx and
GABA concentrations were measured using proton Magnetic Resonance Spectroscopy. Impulsivity, smoking,
alcohol and cocaine use severity and cannabis use were measured using self-report instruments. Results indicate
a trend towards group diﬀerences in Glx. Post-hoc analyses showed a diﬀerence between smokers and healthy
controls (p = 0.04) and a trend towards higher concentrations in smoking polysubstance users and healthy
controls (p = 0.09), but no diﬀerences between smokers and smoking polysubstance users. dACC GABA con-
centrations were not signiﬁcantly diﬀerent between groups. Smoking polysubstance users were more impulsive
than smokers, and both groups were more impulsive than controls. No signiﬁcant associations were observed
between dACC neurotransmitter concentrations and impulsivity and level and severity of smoking, alcohol or
cocaine use or the presence of cannabis use. The results indicate that diﬀerences in dACC Glx are unrelated to
type and level of substance use. No ﬁnal conclusion can be drawn on the lack of GABA diﬀerences due to
assessment diﬃculties. The relationship between dACC neurotransmitter concentrations and cognitive impair-
ments other than self-reported impulsivity should be further investigated.
1. Introduction
Neurobiological models of substance use disorders (SUDs) have
mainly focused on the dopaminergic system (Berridge and
Robinson, 1998; but see Nutt et al., 2015 for a critical appraisal).
Glutamatergic and GABAergic mechanisms in substance depen-
dence have recently become more prominent in models of addiction
(e.g., Li et al., 2013). Glutamate and GABA play a key role in per-
sonality traits associated with addiction, such as impulsivity
(Schmaal et al., 2012a; Silveri et al., 2014). Several Magnetic Re-
sonance Spectroscopy (1H-MRS) studies in humans have shown that
glutamate is aﬀected in substance dependence (e.g., Schmaal et al.,
2012b; Yücel et al., 2007). However, the role of GABA in human
addiction is less well studied and it remains to be investigated
whether glutamate and GABA deviate between diﬀerent substances
of abuse. Moreover, very little is known about the relationship
between these neurotransmitters and risk-related traits, including
impulsivity, in people with (SUDs). However, glutamate levels in
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the Anterior Cingulate Cortex (ACC) have been related to functions
that are aﬀected in SUDs such as delay discounting (e.g., Schmaal
et al., 2012a).
The ACC has been a main region of interest for imaging studies on
SUDs, as this brain region is suggested to play a key role in craving and
relapse to drug-seeking, and impulsivity (Brand et al., 2014; Garavan
and Hester, 2007; Myers and Carlezon, 2010). This region is highly
suitable for 1H MRS studies due to its homogeneous structure, resulting
in several human 1H MRS studies on ACC glutamate concentrations in
SUDs. However, the results are inconsistent with regard to the existence
and direction of ACC glutamate and GABA alterations in SUDs. That is,
both increased (Bauer et al., 2013; Lee et al., 2007; Mon et al., 2012;
Schmaal et al., 2012b; Thoma et al., 2011), decreased (Durazzo et al.,
2016; Ende et al., 2013; Hermann et al., 2012; Mashhoon et al., 2011;
Prescot et al., 2013; Yang et al., 2009; Yücel et al., 2007), as well as no
diﬀerences in ACC glutamate concentrations in substance users com-
pared to non-substance using controls have been reported (Chang et al.,
1999; Gallinat and Schubert, 2007). Similar to the latter ﬁndings, the
literature on ACC GABA concentrations in substance dependent in-
dividuals is also inconsistent. Both lower (Abé et al., 2013; Prescot
et al., 2013; Silveri et al., 2014), as well as no diﬀerences in substance
users compared to non-using controls have been reported (Mon et al.,
2012). These contradictory ﬁndings may be the result of methodolo-
gical diﬀerences, such as the location of the MRS voxel (e.g., dorsal
(Schmaal et al., 2012) or rostral ACC (Yang et al., 2009)) It should be
noted that 1H MRS studies are not always able to diﬀerentiate between
glutamate, glutamine, and other components due to overlap in spectral
assignment, for which the term Glx (a composite measure) is often used
(Ramadan et al., 2013). Therefore, the term Glx is used henceforth as a
proxy measure of glutamate when referring to data acquired in the
current study.
GABA and glutamate concentrations may depend on the number of
substances used. For instance, lower ACC GABA concentrations may be
more pronounced in cocaine dependent subjects with a history of al-
cohol dependence compared to cocaine dependent subjects without
such a history (Ke et al., 2004). Similarly, GABA concentrations in the
dorsolateral prefrontal cortex seem to be more pronounced in poly-
substance users compared to alcohol dependent patients (Abé et al.,
2013). Furthermore, Mason et al. (2006) did not ﬁnd diﬀerences in
glutamate and GABA concentrations between alcohol dependent sub-
jects and healthy controls. However, they did ﬁnd higher glutamate and
lower GABA concentrations when comparing smoking with non-
smoking alcohol dependent subjects. Therefore, we included a group of
cigarette smokers as well as a group of smoking polysubstance users to
investigate group diﬀerences in ACC Glx and GABA concentrations.
This has been shown to be a sensitive method to detect the relation
between the types of substances used and microstructural changes in
the brain (Kaag et al., 2016).
SUDs have also been associated with impaired impulse control and
deviant ACC functioning (Garavan and Hester, 2007; Hester and
Garavan, 2004; Li et al., 2008; Moeller et al., 2001). Furthermore,
higher impulsivity has been positively associated with deviating glu-
tamate concentrations in rodents (see e.g., Pattij and Vanderschuren,
2008), and this association has also been found in cocaine dependent
subjects (Schmaal et al., 2012a). However, no such data are available
on other SUDs and therefore the relationship between neurotransmitter
concentrations and cognitive abnormalities remains unknown.
To address these issues, we compared Glx and GABA concentrations
in the dorsal Anterior Cingulate Cortex (dACC) of cigarette smokers,
smoking polysubstance users and healthy controls. We chose the dACC
as a region of interest since it has been associated with impaired im-
pulse inhibition in cocaine dependence (Garavan and Hester, 2007;
Hester and Garavan, 2004). Furthermore, we examined the relationship
of these neurotransmitter concentrations with self-reported impulsivity
and the level of substance use. Our ﬁrst hypothesis is that there will be
group diﬀerences with regard to Glx and GABA concentrations. More
speciﬁcally, we expect that each substance-using group shows higher
Glx concentrations and lower GABA concentrations compared to
healthy controls. Furthermore, since the use of multiple substances has
been shown to be associated with larger group diﬀerences in neuro-
transmitter concentrations (Abé et al., 2013; Ke et al., 2004; Mason
et al., 2006), our second hypothesis is that smoking polysubstance users
will show larger neurotransmitter deviations from the healthy controls
than smokers. In addition, neurotransmitter concentrations are hy-
pothesized to be associated with self-reported substance use (reported
as the level of substance use severity and the amount of substance use).
Our fourth hypothesis is that there will be group diﬀerences with regard
to self-reported impulsivity. More speciﬁcally, we expect that both
smokers and smoking polysubstance users show higher impulsivity than
healthy controls, and that smoking polysubstance users will show
higher impulsivity compared to smokers. Finally, we hypothesize that
higher self-reported impulsivity levels are associated with higher Glx
and lower GABA concentrations across all three groups.
2. Materials and methods
2.1. Participants
Data (unpublished at time of submission) from two diﬀerent studies
were combined, hereafter referred to as Study A and Study B. Study A
focused on the eﬀects of N-acetylcysteine on dACC neurotransmitter
concentrations of smokers, of which the baseline measures of smokers
(S, n = 48) were included in the current analyses. Study B focused on
neurocognitive measures in cocaine users, who reported the use of
multiple substances and are therefore referred to as polysubstance
users. Those who also smoked cigarettes were included in the current
analyses (SP, n = 61). Healthy controls (HC, n = 90) who do not
smoke or use any substances besides recreational alcohol use were in-
cluded from both studies.
In study A, inclusion criteria were: male; 18–55 years old; smoking
at least 15 cigarettes per day; a desire to quit smoking; a Fagerström
Test Nicotine Dependence (FTND; Heatherton et al., 1991) score of at
least 3, indicating at least a low degree of smoking dependence
(Heatherton et al., 1991), and an Alcohol Use Disorder Identiﬁcation
(AUDIT) score lower than 13, indicating the absence of heavy alcohol
use and/or an alcohol use disorder. In study B, inclusion criteria were:
male; 18–50 years old; non-treatment seeking; and snorting cocaine at
least once per week in the last 6 months. Healthy controls were also
excluded if they reported a history of substance (ab)use or dependence
including nicotine use, and in case of any psychotropic medication use.
Exclusion criteria for all participants were: major medical or neu-
rological disease; lifetime history of psychotic or bipolar disorder; the
presence of contraindication to MRI scanning; and the use of anti-
depressants or antipsychotics. Participants in study B were instructed
not to use alcohol or cocaine ten hours before the session, but partici-
pants from both studies were allowed to smoke ad libitum before the
start of the studies. In addition, participants in study B were excluded if
they ever used heroin, but were not excluded on the use of other sub-
stances. All participants were recruited by means of advertisements and
word of mouth. Written informed consent was acquired before the
beginning of the session. Study A was approved by the Ethics
Committee of the Psychology Department of the University of
Amsterdam, and registered with the Netherlands Trial Registry
(number: NTR3576). Study B was approved by the Ethical Review
Board of the Academic Medical Centre of the University of Amsterdam,
the Netherlands.
2.2. Clinical assessments
For the substance-using groups, the severity of smoking dependence
was assessed using the FTND. For the SP group, the Drug Use Disorder
Identiﬁcation Test (DUDIT; Berman et al., 2005) was used to assess the
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level of cocaine use and related problems. For all participants, the
premorbid level of intellectual functioning was measured using the
Dutch version of the National Adult Reading Test (NART; Schmand
et al., 1991), the AUDIT (Babor et al., 1989) was used to assess the level
of alcohol use and related problems, the Time Line Follow Back method
(TLFB; Sobell and Sobell, 1992) was used to assess cannabis use in the
preceding 6 months, and the Barratt Impulsiveness Scale (BIS-11;
Patton et al., 1995) was administered to assess self-reported im-
pulsivity.
2.3. Magnetic resonance spectroscopy acquisition and processing
Participants of study A and B were scanned on the same scanner.
First, a structural three-dimensional T1-weighted volume
(TR = 8.2 ms; TE = 3.7 ms; 220 slices; voxel size 1 × 1 × 1 mm; ma-
trix size 240 × 187) was acquired in the transverse plane using a
SENSE 32-channel receiver head coil on an Achieva XT 3T head-only
MRI scanner (Philips Healthcare, Best, The Netherlands) at the Spinoza
Centrum of the University of Amsterdam. This structural image was
used to place the MRS voxel in the dACC (see Fig. 1), based on each
individual’s anatomical landmarks. The voxel was placed over the
midline covering both hemispheres, since there was no prior expecta-
tion of diﬀerences in Glx or GABA concentrations between hemispheres.
GABA-edited 1H J-diﬀerence spectra were acquired using a MEGA-
PRESS sequence (Waddell et al., 2007; TR = 2000 ms; TE = 73 ms;
voxel size 35 mm× 20 mm× 15 mm, 384 transients). During the odd
transients, a 15.64 ms sinc-center editing pulse (64 Hz full width at half
maximum) was applied at 1.9 ppm and 4.6 ppm in an interleaved
manner to speciﬁcally excite GABA and suppress water, respectively.
In the current study, Glx concentrations are reported as the best
available proxy measure of glutamate, due to overlap in spectral as-
signment of glutamate, glutamine, and other components. The applied
1H MRS measurements allowed us to quantify the concentration of Glx
and GABA in the dACC. The even and the J-diﬀerence (odd-even) ac-
quisitions were analyzed using LCModel (Linear Combination of Model
spectra; Provencher, 1993). Total creatine (Cre + PCr) and total N-
acetyl aspartate (NAA + NAAG) were quantiﬁed from the even acqui-
sitions, and Glx, GABA, and again NAA were quantiﬁed from the dif-
ference acquisitions. Glx and GABA were normalized to the diﬀerence-
spectra NAA, and the even-spectra NAA was normalized to creatine.
This procedure calibrated signal amplitude across even and diﬀerence
acquisitions within each subject, enabling Glx and GABA concentra-
tions to be expressed in units of creatine (see for details Waddell et al.,
2011, 2007). Cramer–Rao Lower Bounds (CRLBs) of 20% were used for
each individual peak as a quality criterion (Provencher, 1993). All
spectra were also visually inspected. Scans that did not meet de CRLB
criterion or passed the visual inspection were excluded from analyses.
CRLBs for all metabolites in all subjects were between 3 and 9%. Ad-
ditional indicators for the quality of the spectra were mean (± SD)
signal to noise ratio and mean (± SD) full width half maximum
(FWHM). The SNR for the heavy smokers was 4.20 (0.89), for smoking
polysubstance users it was 4.16(1.13), and 4.32 (1.04) for the healthy
controls. The FWHM for the heavy smokers was 0.05 (0.02), for the
smoking polysubstance users it was 0.06 (0.02), and 0.05 (0.02) for the
healthy controls.
2.4. Statistical analyses
Data were checked for outliers and normal distribution. Non-
parametric tests were used if a variable did not meet the criterion of
normal distribution after log-transformation. Diﬀerences between
groups were analyzed using one-way ANOVAs, followed by planned
pairwise comparisons to test for possible group diﬀerences. To ac-
count for multiple testing, a Bonferroni correction of 2 was applied
for the analyses on neurotransmitter concentrations (Glx and
GABA). Since the results on Glx were trend signiﬁcant, the post-hoc
analyses were exploratory and therefore performed without cor-
rection for multiple comparisons. Eta squared is reported as an
index of eﬀect size. Bivariate correlation analyses were used to
investigate associations between neurotransmitters and im-
pulsivity. For exploratory purposes, multiple regression analyses
were used to investigate, per group, associations between neuro-
transmitter concentrations and the level of substance use, as well as
the severity of substance use disorders for alcohol, tobacco and
cocaine, and cannabis used, as measured with the AUDIT, FTND,
DUDIT, and TLFB, respectively. For each analysis, only the sub-
stances that were used by that particular group were entered in the
regression analyses.
3. Results
3.1. Sample characteristics
After excluding participants due to unreliable MRS spectra, 30/
48 (62.5%) from the S group, 38/61 (62.3%) from the SP group, and
61/90 (67.7%) from the HC group were included in the analyses.
Demographic, clinical, and neurotransmitter information is dis-
played in Table 1. The groups were of similar age (H2 = 3.00,
p = 0.22), but diﬀered in IQ (F2,126 = 4.20, p = 0.017). Post-hoc
analyses showed that the S group did not diﬀer from the HC group
(p = 0.981), but that the SP group had lower IQ compared to the
HC group (p = 0.008) and the S group (p = 0.023). Since IQ was
not a matching criterion and represents a group characteristic, IQ
was not entered as a covariate in the analyses on group diﬀerences
in Glx and GABA. Moreover, IQ was not correlated with Glx
(p = 0.71) or GABA (p = 0.69). There was no diﬀerence between
the S and SP groups with regard to nicotine dependence as mea-
sured with the FTND (t66 = 0.539, p = 0.59). There were sig-
niﬁcant group diﬀerences in alcohol use and related problems as
measured with the AUDIT (F2,126 = 51.87, p < 0.001). Post-hoc
Fig. 1. Spectroscopy details. Left: placement of the MRS voxel in the dorsal Anterior Cingulate Cortex (dACC). Middle: Example spectrum for the diﬀerence acquisition from the dACC
voxel. Right: Example spectrum for the even acquisition from the dACC voxel.
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analyses showed that the SP group had higher AUDIT scores com-
pared to the HC (p < 0.001) and the S group (p < 0.001), but that
there was no diﬀerence in AUDIT scores between the S and HC
groups. However, AUDIT scores were not correlated with Glx
(p = 0.45) or GABA (p = 0.72). Moreover, since cocaine use is
highly related to alcohol use and therefore high AUDIT scores are
inherently connected to cocaine use (EMCDDA, 2009; Connor et al.,
2014; Tang et al., 2007), AUDIT scores were not included as a
covariate in the analyses when comparing the S and SP groups to
the HC group on brain Glx and GABA measures to avoid the risk of
overcorrection resulting in a serious reduction of variance in Glx
and GABA measures (Miller and Chapman, 2001). Also see section
‘substance use and neurotransmitter levels’ for the association be-
tween neurotransmitter concentrations and AUDIT scores.
3.2. Glx and GABA concentrations
To account for multiple testing, a Bonferroni correction of 2 was
applied for the analyses on neurotransmitter concentrations (Glx
and GABA), resulting in an adjusted alpha level of 0.025. With re-
gard to Glx concentrations, there was a trend signiﬁcant group
diﬀerence (F2,126 = 2.71, p = 0.07; see Fig. 2). Since this suggests
the presence of individual group diﬀerences in Glx, planned group
comparisons were performed to explore these potential diﬀerences.
Since these analyses were exploratory, no correction for multiple
comparisons was applied. In these post-hoc group comparisons the
S group had higher dACC Glx concentrations compared to the HC
group (p = 0.04; η2 = 0.05) and the SP group tended to have
higher dACC Glx concentration than the HC group (p = 0.09;
η2 = 0.03). No diﬀerence in dACC Glx concentrations was found
between the S and SP groups (p = 0.67). There were no between
group diﬀerences in GABA concentrations (F2,105 = 0.041,
p = 0.96; see Fig. 2).3 Additionally, there were no between group
diﬀerences with respect to total N-Acetyl Aspartate (NAA + NAAG;
F2,126 = 0.334, p = 0.72, η2 = 0.005) and total creatine (Cre
+ PCr; F2,126 = 1.456, p = 0.24, η2 = 0.023). Also, there were no
group diﬀerences in regional grey matter (F2,126 = 1.625, p = 0.20,
η2 < 0.001) or white matter (F2, 126 = 0.849, p = 0.43,
η2 < 0.001) volume within the dACC voxel for those individuals
included in the analyses on Glx diﬀerences. In addition, there were
no group diﬀerences in grey matter (p = F2,126 = 0.346, p = 0.71,
η2 < 0.001) or white matter (F2,126 = 0.172, p = 0.84,
η2 < 0.001) for those included in the analyses on GABA diﬀer-
ences.
3.3. Impulsivity and neurotransmitter levels
The groups were signiﬁcantly diﬀerent from each other with regard
to BIS-11 score (F2,122 = 26.83, p < 0.001; see Table 1). Planned
comparisons showed that the HC group had the lowest BIS-11 scores,
and that their score was signiﬁcantly diﬀerent from the S (p = 0.008)
the SP group (p < 0.001). In addition, the SP group scored sig-
niﬁcantly higher on the BIS-11 than the S group (p = 0.001). However,
there was no association between BIS-11 score and Glx (p = 0.85) or
GABA concentrations (p = 0.34; see Fig. 3).
Table 1
Between group diﬀerences in demographic, clinical and neurobiological outcomes.
HC S SP Fa/H(df)b/Uc P-value Eﬀect size (η2)
N = 61 N = 30 N= 38
Mean SD Mean SD Mean SD
Age 32.10 9.69 35.87 10.48 32.66 7.45 3.00(2)b 0.22 0.02
IQ (NART) 104.9 8.60 105.00 8.90 99.90 9.60 4.196a 0.017ee 0.06
Alcohol (units/week) 4.87 6.36 7.23 6.39 25.98 25.49 47.34(2)b < 0.0001 0.29
AUDIT scores 5.67 3.75 6.10 2.91 13.37 4.58 51.87a < 0.0001 0.45
Cigarettes/week – – 155.24 67.79 115.22 61.35 6.504a 0.013 0.09
FTND scores – – 6.07 1.96 5.79 2.21 0.291a 0.59 0.004
DUDIT scores – – – – 18.19 5.00 – – –
Cocaine/week (g) – – – – 2.29 1.32 – – –
Cannabis/week (joints) – – 0.09 0.19 4.73 7.19 67.00c 0.01 0.18
BIS-11 59.27 7.92 64.89 9.85 72.94 9.96 26.83a < 0.001 0.31
Glx 0.62 0.11 0.68 0.13 0.67 0.13 2.71a 0.07 0.04
GABA 0.20 0.04 0.20 0.09 0.20 0.04 0.04a 0.96 0.001
Abbreviations: AUDIT, Alcohol Use Disorder Identiﬁcation Test; BIS-11, Barratt Impulsiveness Scale version 11; DUDIT, Drug Use Disorder Identiﬁcation Test; FTND, Fagerström Test for
Nicotine Dependence; GABA, gamma-aminobutyric acid, referenced to creatine; Glx, composite measure of glutamate and glutamine, referenced to creatine; HC, Healthy Controls; NART,
National Adult Reading Test; S, Smokers; SD, Standard Deviation; SP, Smoking Polysubstance Users.
a p-values represent univariate ANOVAs.
b p-values represent non-parametric univariate ANOVAs.
c p-values represent non-parametric t-test.
Fig. 2. Concentration of Glx (left) and GABA (right)
in the dorsal Anterior Cingulate Cortex per group
85(M ± SD). There was a trend signiﬁcant between
group diﬀerence with regard to Glx (p = 0.07), but
no between group diﬀerence with regard to GABA
(p = 0.96).
3 There appeared to be a subtraction error at 3.2 ppm in a considerable proportion of
the spectra (smokers: 80%, smoking polysubstance users: 69%, healthy controls: 60%),
which might have led to a distortion in the quantiﬁcation of GABA. However, there was
no diﬀerence in proportion of subtraction error between groups (χ2(2) = 1.553,
p = 0.460).
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3.4. Substance use and neurotransmitter levels
Additional exploratory analyses were performed to investigate
possible associations between substance use levels and substance use
disorder severity with dACC neurotransmitter concentrations.
In the HC group, multiple regression did not show a signiﬁcant re-
lation between AUDIT scores and Glx (F1,60 = 0.001, p = 0.97) or
GABA concentrations (F1,47 = 0.166, p = 0.69), and no signiﬁcant re-
lations between the amount of alcohol used and Glx (F1,56 = 0.084,
p = 0.77) or GABA concentrations (F1,44 = 0.303, p = 0.59).
In the S group, there also was no signiﬁcant relation between AUDIT
and FTND scores and Glx (F2,29 = 0.120, p = 0.89) or GABA con-
centrations (F2,33 = 0.203, p = 0.82), and no signiﬁcant relation be-
tween the amount of alcohol and the number of cigarettes and Glx
(F2,29 = 0.186, p = 0.83) or GABA concentrations (F2,33 = 0.112,
p = 0.90).
Finally, in the SP group there were no signiﬁcant relations of AUDIT
score, FTND score, DUDIT score, and cannabis use with Glx
(F4,36 = 0.044, p = 0.99) or GABA concentrations (F4,24 = 0.86,
p = 0.51), and no signiﬁcant relations of alcohol, cigarette, cocaine and
cannabis use with Glx (F4,37 = 0.712, p = 0.59) or GABA concentra-
tions (F4,25 = 1.021, p = 0.42).
4. Discussion
This study investigated diﬀerences in dACC Glx and GABA con-
centrations and impulsivity between cigarette smokers, smoking poly-
substance users, and healthy controls. In line with our ﬁrst hypothesis,
there was a trend towards group diﬀerences in dACC Glx concentra-
tions. Furthermore, in contrast to our ﬁrst hypothesis, there were no
between group diﬀerences in dACC GABA concentrations. Post hoc
analyses showed that both substance using groups tended to have
higher Glx concentrations compared to healthy controls, but that there
was no diﬀerence between both substance using groups, which refutes
our second hypothesis. It should be noted that no correction for mul-
tiple comparison was applied since these comparisons were performed
exploratory. In contrast to our third hypothesis, there were no sig-
niﬁcant correlations between dACC neurotransmitter concentrations
and substance use severity, or the amount of substance use. In line with
our fourth hypothesis, there were group diﬀerences with regard to
impulsivity. Post hoc analyses showed that smokers and smoking
polysubstance users had higher BIS-11 scores than healthy controls, and
smoking polysubstance users showed higher scores than smokers.
However, in contrast to our ﬁfth hypothesis, there were no signiﬁcant
correlations between dACC neurotransmitter concentrations and self-
reported impulsivity.
The trend towards increased Glx concentrations in smokers and
smoking polysubstance users versus healthy controls are in line with
previous research showing higher dACC glutamate concentrations
(Bauer et al., 2013; Lee et al., 2007; Schmaal et al., 2012b; Thoma et al.,
2011). However, no diﬀerence in dACC Glx concentrations between
smokers and smoking polysubstance users were found, which
contradicts previous ﬁndings of larger diﬀerences in multiple versus
single substance users (Abé et al., 2013; Ke et al., 2004; Mason et al.,
2006). Since the substance using groups did not diﬀer in the level of
nicotine dependence, this may indicate that alterations in Glx con-
centrations are possibly more related to smoking dependence than to
other types of substance use. However, since there were no signiﬁcant
correlations between glutamate concentrations and nicotine use se-
verity (or alcohol and cocaine use severity), higher glutamate con-
centrations may be associated with the presence of (underlying pro-
cesses related to) substance dependence in general, unspeciﬁc to the
type of substance. Other explanations could be that there is a ‘threshold
eﬀect’ resulting in aﬀected glutamate concentrations after someone has
used for a certain period of time of with a speciﬁc intensity of substance
use, or the cardiovascular eﬀect of the used substances that cause a
circulatory compromise in the dACC. More extensive studies should be
performed to further disentangle this diﬀerential eﬀect.
As expected, we found between group diﬀerences in self-reported
impulsivity with the highest impulsivity scores in smoking poly-
substance users followed by smokers and the lowest in healthy controls.
However, impulsivity was not signiﬁcantly correlated to dACC Glx or
GABA concentrations. This is not in line with previous studies showing
a signiﬁcant correlation between impulsivity and glutamate con-
centrations (Pattij and Vanderschuren, 2008; Schmaal et al., 2012b).
However, the review by Pattij and Vanderschuren (2008) is based on
animal studies using diﬀerent indicators for impulsivity. The study of
Schmaal et al. (2012b) tested in only 8 treatment seeking cocaine de-
pendent patients with similar BIS-11 scores but much higher AUDIT
scores than the cocaine users in the current study (21.3 vs. 13.4).
In contrast to previous studies (Abé et al., 2013; Durazzo et al.,
2016; Ke et al., 2004; Prescot et al., 2013; Silveri et al., 2014), we did
not ﬁnd diﬀerences in dACC GABA concentrations between the sub-
stance using groups and healthy controls, or between smokers and
smoking polysubstance users. Possible explanations include diﬀerences
in methodology between the previous studies and the current study. For
instance, previous studies recruited mainly non-smokers (Ke et al.,
2004; Prescot et al., 2013; Silveri et al., 2014), whereas both substance
using groups in the current study were smokers. Another explanation
could be the duration of abstinence at the moment of testing since the
aforementioned studies all tested GABA concentrations after at least
one week of abstinence. In the current study, the substance using par-
ticipants were allowed to smoke ad libitum until the session. However,
Mon et al. (2012) also found no diﬀerences in GABA concentrations
despite a period of abstinence.
Although at trend level, our ﬁndings support the literature on de-
viating glutamate concentrations and thus point to the potential of
(anti)glutamatergic agents for the treatment of substance dependence.
For instance, acamprosate (commonly used in the treatment of alcohol
dependence) and N-acetylcysteine (commonly used as a mucolytic
agent in cough medicine) have both been found to reduce glutamate
concentrations in alcohol and cocaine dependent individuals, respec-
tively (Schmaal et al., 2012b; Umhau et al., 2010). In addition, several
studies indicate that N-acetylcysteine is eﬀective in the treatment of
Fig. 3. Correlation between Glx (left) and GABA
(right) with BIS-scores per group. There was no as-
sociation between BIS-11 score and Glx (p = 0.85)
or GABA (p = 0.34).
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other substance use disorders (for reviews, see Deepmala et al., 2015;
McClure et al., 2014). More research is needed to investigate the exact
mechanisms underlying the eﬃcacy of such glutamatergic agents.
Major strengths of this study are the relatively large samples and the
direct comparison of neurotransmitter concentrations and impulsivity
between smokers with or without concurrent polysubstance use and
non-substance using healthy controls. Another strength of this study is
the simultaneous assessment of neurobiological and behavioral mea-
sures. The current study also has limitations. First, only male partici-
pants were recruited in both studies. Although this may lead to more
homogeneous groups and thereby strengthens the results of the study,
this also limits the generalizability of the results to the general popu-
lation. Second, as mentioned before, the subjects were recruited as part
of two individual studies to answer study-speciﬁc research questions.
However, all participants were recruited in the same way and scanned
in the same period with the same MRI scanner. Third, there is the issue
of the use of multiple substances, especially in the group of smoking
polysubstance users. Even though this resembles most cocaine users in
the community and in treatment (EMCDDA, 2009; Connor et al., 2014),
who are suggested to be also dependent on alcohol and/or tobacco
(Tang et al., 2007), it could be that diﬀerent substances have a diﬀerent
or even opposite eﬀect on glutamate concentrations. This may also play
an important role in the treatment of polysubstance users. In addition,
for cannabis only the eﬀect of the amount of cannabis use was analyzed,
due to the lack of a questionnaire assessing problematic cannabis use in
the original studies. Even though our sample size was fairly large for an
imaging study, even larger (possibly multi-site) studies would be
needed to study the neurobiological eﬀects of polysubstance use.
Fourth, to ensure overall good quality of the MRS data some partici-
pants had to be excluded from the analyses on Glx and GABA con-
centrations, due to unreliable MRS spectra. However, similar propor-
tions had to be excluded in all three groups and there was no diﬀerence
in sociodemographic and clinical characteristics between those ex-
cluded and those included in the current analyses. In addition, we were
unable to verify if potential head movement during scanning aﬀected
scan quality. This should be taken into account in future studies. Fur-
thermore, the results concerning GABA should be interpreted with
caution, due to the presence of a choline peak at 3.2 ppm that might
have distorted the quantiﬁcation of GABA. This did not inﬂuence the
quantiﬁcation of Glx. Fifth, even though the BIS-11 is widely used to
assess impulsivity, additional measures of behavioral impulsivity may
capture diﬀerent aspects of impulsivity unrelated to self-reported im-
pulsivity (Broos et al., 2012; Kräplin et al., 2014). Finally, the 1H MRS
sequences that we applied in the current study were not optimized to
diﬀerentiate between glutamate, glutamine and glutathione because
they largely overlap in their chemical shift range (Ramadan et al.,
2013). Therefore, the composite measure Glx was used as a proxy
measure of glutamate, but some contribution of glutamine and glu-
tathione cannot be ruled out.
In conclusion, the current study found indications of dACC Glx
diﬀerences between substance using groups and healthy controls, but
not between the substance using groups. Moreover, Glx concentrations
were not associated with the level of substance use and therefore the
observed increase in Glx in substance users is not just a consequence of
substance use itself. Furthermore, no diﬀerences in dACC GABA con-
centrations were found. There were group diﬀerences in self-reported
impulsivity, but self-reported impulsivity was not signiﬁcantly corre-
lated with dACC Glx or GABA concentrations. More research is needed
to investigate the relationship between dACC neurotransmitter con-
centrations and aspects of cognitive impairment other than self-re-
ported impulsivity.
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